Home / BPC-157 calculator

BPC-157 reconstitution calculator

BPC-157 has no FDA-approved product and no established human dose, so this page gives no dose. It does the math for whatever your prescriber specified: enter the mg on your vial, the water you add and the dose, or use the table to see how much each syringe unit holds.

–
Concentration–
Per 1 unit (0.01 mL)–
Volume per dose–
Doses per vial–

How much BPC-157 is in each unit

mcg per unit (0.01 mL) on a U-100 syringe. Vial sizes are examples; read the mg on your own vial. Not FDA-approved; no established human dose.

Water2 mg vial5 mg vial10 mg vial
1 mL20 mcg50 mcg100 mcg
2 mL10 mcg25 mcg50 mcg
3 mL6.7 mcg16.7 mcg33.3 mcg
5 mL4 mcg10 mcg20 mcg

To turn a prescribed dose into units: dose in mcg ÷ mcg per unit. The calculator above does it and checks it fits your syringe. Evidence and US status: BPC-157 reference page.

Units are not mg. "10 units" on a syringe is 0.1 mL. How many mg that holds depends on how the vial was mixed. If a prescription is written in units, confirm the concentration it assumes.

Questions

How many mcg is 1 unit of BPC-157?
It depends only on the mix. Each unit is 0.01 mL, so it holds (mg in vial ÷ mL of water) × 10 mcg. A 2 mg vial with 2 mL of water holds 10 mcg per unit.
What is the dose of BPC-157?
There is no established human dose. No dose-finding trial in humans has been published. Early ulcerative colitis studies (enema, 2003-2005) were only published as abstracts. A 2025 safety pilot gave it by IV to 2 healthy adults; no side effects were reported. Two people cannot establish safety. FDA reviewers cited signals of clotting and liver effects in repeat-dose animal studies.
Is BPC-157 FDA-approved?
Not approved by the FDA for any use. FDA removed it from its "significant safety risk" compounding list in April 2026 after the nomination was withdrawn, and an FDA advisory committee voted in favor of allowing pharmacy compounding in July 2026, against the recommendation of FDA staff. On October 30, 2026, HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies that compound it for a named patient with a prescription, under listed conditions and routes. That is not an FDA approval and says nothing about safety or effectiveness. The draft policy names the acetate form for injection under the skin or into muscle, oral and topical use.

Sources

  1. FDA: Certain bulk drug substances for compounding that may present significant safety risks
  2. Federal Register (public inspection) 2026-07361: peptide category changes
  3. PharmExec: FDA advisory committee votes to loosen restrictions on peptides (Jul 2026)
  4. FDA 510(k) K212499: BD insulin syringes for U-100 insulin

Last checked 2026-11-16. How we pick and check sources: methodology.